Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,404 across all filing types
Latest filing 2018-11-13 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
FARXIGA SIGNIFICANTLY REDUCED HOSPITALISATION FOR
Regulatory Filings
2018-11-13 English
AstraZeneca to divest US Synagis rights to Sobi
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated 13 November 2018, indicating it is a regulatory announcement disseminated via the London Stock Exchange's news service (RNS). The content details a significant corporate transaction: AstraZeneca divesting US rights to Synagis and gaining rights related to MEDI8897 to Sobi. This is a material event announcement concerning asset disposal and strategic realignment. Since it is a formal, time-sensitive announcement distributed through the official regulatory channel (RNS) and does not appear to be a full financial report (like 10-K or IR), the most appropriate classification is the general regulatory announcement category, RNS. The document length (8173 chars) is substantial, but the format and source strongly point to an RNS filing.
2018-11-13 English
US FDA accepts regulatory submission for Lynparza
Legal Proceedings Report Classification · 99% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's news service (RNS). The content details a specific regulatory event: the US FDA accepting a supplemental New Drug Application (sNDA) for Lynparza and granting Priority Review. This is a material corporate event announcement concerning regulatory progress, not a full financial report (like 10-K or IR) or a general press release about results (ER). Since it is a formal regulatory announcement distributed through the RNS system that doesn't fit perfectly into other specific categories like Director's Dealing (DIRS) or Dividend Notice (DIV), the most appropriate classification is the general regulatory filing category, RNS.
2018-11-12 English
Farxiga significantly reduced hospitalisation for
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and a date, followed by a press release format announcing positive results from a clinical trial (DECLARE-TIMI 58) for the drug Farxiga. It includes contact information for Media Relations and Investor Relations, and concludes with a standard disclaimer referencing RNS, the news service of the London Stock Exchange, and the FCA. This structure is characteristic of a general regulatory announcement disseminated via the RNS system, rather than a specific financial report like a 10-K, IR, or ER. Since it is a broad regulatory announcement that doesn't fit the more specific categories (like DIV, CAP, or ER), the appropriate fallback is RNS.
2018-11-12 English
AZN: YEAR-TO-DATE AND Q3 2018 RESULTS
Regulatory Filings
2018-11-08 English
AZN: Year-to-Date and Q3 2018 Results
Earnings Release Classification · 100% confidence The document text contains detailed financial performance metrics for 'Year-to-Date and Q3 2018 Results' for AstraZeneca PLC, including Product Sales, Operating Profit, EPS, and specific drug performance (Oncology, CVRM, Respiratory). It also includes management commentary from the CEO and guidance for FY 2018. This structure is characteristic of an official announcement of periodic financial results, which aligns with the Earnings Release (ER) definition, which covers 'initial announcement of quarterly/periodical financial results (key highlights only)'. Although it is quite detailed, it is the primary release of the period's financial performance, distinct from a comprehensive 'Interim Report' (IR) or the full 'Annual Report' (10-K). The presence of the RNS Number (7022G) and the date (08 November 2018) confirms it is a regulatory announcement of earnings. 9M 2018
2018-11-08 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.